Form 4: Alnylam Pharmaceuticals CEO Yvonne Greenstreet Reports Stock Transactions

Alnylam Pharmaceuticals CEO Yvonne Greenstreet reports acquisition of restricted stock units and stock options, as well as sales of common stock to cover tax obligations.

Summary

• On March 3, 2025, Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, reported transactions involving the company's stock.
• Greenstreet acquired 17,965 restricted stock units (RSUs) and 36,293 stock options.
• She also sold shares of common stock to cover tax withholding obligations related to the vesting of RSUs.
• The sales were executed in multiple transactions at weighted average prices ranging from $242.37 to $248.36 per share.
• Following these transactions, Greenstreet directly owns 98,635 shares of common stock and indirectly owns 407 shares through a managed account and 36,293 stock options.
• The reported transactions also include 5,921 unvested RSUs that were previously reported.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of RSUs and stock options indicates confidence, while the stock sales are routine for tax purposes.

Positives

• The acquisition of RSUs and stock options suggests confidence in the company's future performance.
• The vesting schedule of the stock options incentivizes long-term commitment from the CEO.

Negatives

• The sale of shares to cover tax obligations, while common, slightly reduces the CEO's direct holdings in the company.

Risks

• The value of the RSUs and stock options is contingent on the company's stock price performance.
• Future tax liabilities associated with vesting RSUs could lead to further sales of common stock.

Future Outlook

The reported transactions reflect ongoing compensation and equity ownership adjustments for the CEO, aligning her interests with those of shareholders.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's prospects. The acquisition of RSUs and stock options is a common practice in the pharmaceutical industry to incentivize executives.

Comparison to Industry Standards

• Stock option grants and RSU awards are standard compensation practices for executives in publicly traded pharmaceutical companies like Alnylam.
• Companies such as Moderna, BioNTech, and Vertex Pharmaceuticals also utilize similar equity-based compensation plans to align executive incentives with shareholder value.
• The vesting schedules and exercise prices are generally comparable to industry norms, designed to reward long-term performance and retention.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• They primarily reflect internal compensation adjustments and tax obligations.

Key Dates